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ARTICLE
RSPO3 impacts body fat distribution and regulates
adipose cell biology in vitro
Nellie Y. Loh 1, James E. N. Minchin 2,3, Katherine E. Pinnick 1, Manu Verma 1, Marijana Todorčević1,
Nathan Denton 1, Julia El-Sayed Moustafa 4, John P. Kemp5,6, Celia L. Gregson 7, David M. Evans 5,6,
Matt J. Neville 1,8, Kerrin S. Small 4, Mark I. McCarthy1,8,9, Anubha Mahajan1,9, John F. Rawls 2,
Fredrik Karpe1,8✉ & Constantinos Christodoulides 1✉
Fat distribution is an independent cardiometabolic risk factor. However, its molecular and
cellular underpinnings remain obscure. Here we demonstrate that two independent GWAS
signals at RSPO3, which are associated with increased body mass index-adjusted waist-to-hip
ratio, act to specifically increase RSPO3 expression in subcutaneous adipocytes. These var-
iants are also associated with reduced lower-body fat, enlarged gluteal adipocytes and insulin
resistance. Based on human cellular studies RSPO3 may limit gluteofemoral adipose tissue
(AT) expansion by suppressing adipogenesis and increasing gluteal adipocyte susceptibility
to apoptosis. RSPO3 may also promote upper-body fat distribution by stimulating abdominal
adipose progenitor (AP) proliferation. The distinct biological responses elicited by RSPO3 in
abdominal versus gluteal APs in vitro are associated with differential changes in WNT sig-
nalling. Zebrafish carrying a nonsense rspo3 mutation display altered fat distribution. Our
study identifies RSPO3 as an important determinant of peripheral AT storage capacity.
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Fat distribution is a heritable trait and an independent pre-dictor of type 2 diabetes (T2D) and cardiovascular disease.While upper-body obesity is associated with adverse cardi-
ometabolic outcomes, lower-body fat accumulation provides
protection against T2D and atherosclerosis1. This is best exem-
plified by patients with partial lipodystrophy, a group of rare,
heterogeneous disorders characterised by selective lower-body fat
loss and development of severe insulin resistance2. The adverse
consequences of truncal obesity are partly due to the anatomic
location of visceral fat3. Complementarily, compared to sub-
cutaneous (SC) abdominal (hereafter referred to as abdominal)
and visceral, i.e., android adipose tissue (AT) depots, gluteofe-
moral AT displays differential fatty acid (FA) handling1,3. By
favouring long-term FA storage, lower-body fat may protect
extra-adipose tissues from ectopic fat deposition and lipotoxicity.
Gluteofemoral AT may also promote systemic insulin sensitivity
by secreting a more beneficial adipocytokine profile than android
fat4.
In children and adolescents, AT expansion occurs via an
increase in both adipocyte number (hyperplasia) and size
(hypertrophy). In contrast, in adults, abdominal AT expands by
adipocyte hypertrophy while growth of lower-body fat might
occur via hyperplasia5,6. Around one-tenth of the total adult fat
cell pool is also renewed every year5. These findings highlight the
importance of continuous adipocyte generation in the growth and
maintenance of AT depots. Adipocytes originate from adipose
progenitors (APs); mesenchymal stem cells and preadipocytes. It
is now established that different fat depots arise from unique APs
with distinct biological properties and developmental gene
expression signatures2,7–10, which give rise to specialised adipo-
cytes with diverse functional traits. These findings have led to the
hypothesis that developmental pathways play a critical role in
establishing AP and adipocyte identity and thus in determining
the size of fat depots, by modulating adipocyte number and size
in each depot. Consistent with this theory, annotation of genome-
wide association study (GWAS) meta-data revealed enrichment
for developmental genes at loci influencing waist-hip ratio
adjusted for BMI (WHRadjBMI), a surrogate measure of fat
distribution11. Relevant to this work, genetic variants at the
RSPO3 locus were shown to be the strongest genetic determinants
of WHRadjBMI12 although, the causal variants, cis-effector gene
(s) and target tissue(s) at this locus have not been mapped.
WNTs are secreted glycoproteins that act locally, via multiple
pathways, to regulate embryonic development and adult tissue
homoeostasis13. In the best characterised, canonical cascade,
WNT binding to their receptors leads to nuclear accumulation of
the transcriptional co-activator β-catenin and increased WNT
target gene expression. Besides WNTs, another group of secreted
proteins, R-spondins (RSPO1-4) also amplify WNT pathway
activity by engaging LGR4-6 receptors to increase the cell
membrane density of WNT receptors14. Canonical WNT sig-
nalling plays a key role in stem cell and AP biology13,15,16.
Accordingly, R-spondins potently stimulate the expansion of
diverse adult stem cell types in vitro and in vivo and function as
organ size regulators14,17–19. Lineage tracing studies have also
identified LGR5 and LGR6 as exquisite adult stem cell markers in
several adult mouse tissues20. LGR6 was additionally shown to
mark mouse APs21.
Prompted by these findings and the aforementioned GWAS
meta-data12 we investigated the molecular, cellular and whole-body
effects of WHRadjBMI-associated alleles at RSPO3. Herein, we
demonstrate that WHRadjBMI-increasing alleles at this locus act to
increase RSPO3 expression specifically in SC AT. In human cellular
studies, we further show that RSPO3 functions to modulate AP and
adipocyte biology. Consistent with these findings, a nonsense rspo3
mutation is associated with altered fat distribution in zebrafish.
Results
Adipose-specific RSPO3-regulation mediates WHR associa-
tions. GWAS results have identified associations between at least
two independent signals at RSPO3 and WHRadjBMI12. Asso-
ciations at both the sentinel (rs72959041) and secondary
(rs1936807) single-nucleotide variants (SNVs) were stronger in
females. We extended these findings by mining genotype and
dual-energy X-ray absorptiometry (DXA) data from over 4500
adults from the Oxford Biobank (OBB) (Table 1). In the case of
the secondary signal we used rs9491696 as a proxy for rs1936807
based on high mutual linkage disequilibrium (LD) (r2= 0.89). As
the two association signals described are in perfect LD (Dʹ= 1),
data for both the index and secondary SNVs are shown with and
without adjustment for rs9491696 and rs72959041 genotype
respectively (Table 1). We found that the WHRadjBMI-
increasing alleles at both rs72959041 and rs9491696 were asso-
ciated with a redistribution of fat from the lower- to the upper-
body, which appeared to be driven by a reduction in leg fat mass
at both signals and a concomitant increase in android fat mass at
rs72959041 (Table 1). Both signals were also associated with
insulin resistant phenotypes based on data from the largest
available GWAS meta-analyses for multiple traits (Supplementary
Table 1). Notably, the association of the secondary signal as
represented by rs1936807, with fasting insulin was stronger in
women consistent with its sexually dimorphic association with fat
distribution (male: β= 0.0073, p-value= 0.06; female: β= 0.016,
p-value= 3.2 × 10−5, sex-difference p-value= 3 × 10−5) (data
from the MAGIC Investigators, https://www.magicinvestigators.
org/Lagou et al.).
We next sought to refine the location of the causal variants
responsible for the GWAS associations at RSPO3 by constructing
credible sets that collectively accounted for ≥99% of the posterior
probability of association, using data from the GIANT con-
sortium and UK Biobank combined meta-analysis12. The causal
variant responsible for the primary WHRadjBMI association
signal at RSPO3 was resolved to a single SNV, rs72959041
(Supplementary Data 1). Based on chromatin-state maps this
variant maps to an AT enhancer element22. To determine if this
signal was associated with a cis-expression quantitative trait locus
(eQTL) in AT, we examined RSPO3 messenger RNA (mRNA)
abundance in abdominal and gluteal fat biopsies from 200 adults
(Supplementary Table 2). Compared with females homozygous
for the common allele, female carriers of the WHRadjBMI-
increasing allele at rs72959041 displayed higher RSPO3 expres-
sion in both fat depots (Supplementary Fig. 1a, b). We confirmed
and extended this result by demonstrating allelic expression
imbalance (AEI) in a subgroup of samples from seven female and
seven male heterozygous subjects (Supplementary Table 3) using
a tagging, 5′ UTR RSPO3 SNV (rs577721086, r2= 0.98 with
rs72959041) (Fig. 1a, b). Robust cis-eQTL effects at rs72959041
were also detected in femoral AT in GTEx23 and three
independent studies of expression in abdominal AT (TwinsUK,
METSIM24, and deCODE25) (Supplementary Table 4). The cis
association at rs72959041 was specific to SC AT, as no eQTL
signal was observed in visceral fat or 44 other tissues in GTEx.
Formal co-localisation analysis using coloc confirmed that the
WHRadjBMI GWAS association at rs72959041 and the abdom-
inal AT cis-eQTL were explained by the same causal variant
(Fig. 1c and Supplementary Data 1). No other gene mapping
within 1 MB of rs72959041 was associated with an eQTL in any
tissue in GTEx or in abdominal AT from the METSIM cohort,
indicating that RSPO3 is the likely mediator of the WHRadjBMI
association at this signal. Finally, AEI analyses in fractionated
abdominal and gluteal AT from ten females and three males
established that the WHRadjBMI-increasing allele at rs72959041
was associated with increased RSPO3 expression in mature
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adipocytes (Fig. 1d, e, Supplementary Fig. 1c, d and Supplemen-
tary Table 5). A weaker AEI signal was also observed in
abdominal APs.
The causal variant responsible for the association at rs9491696
could not be resolved beyond a set of 13 SNVs in high mutual LD
(r2 ≥ 0.84) spanning a ~ 27 KB interval (Supplementary Data 1).
Two of these associated variants overlap enhancer histone marks
in AT22. At this signal, the WHRadjBMI-increasing allele was not
associated with elevated RSPO3 expression in either abdominal or
gluteal AT from both sexes after excluding carriers of the effect
allele at rs72959041 from analyses (Supplementary Fig. 1e, f).
However, using samples from a subgroup of 15 female and 17
male heterozygous subjects (Supplementary Table 6) we demon-
strated robust AEI using a tagging, exonic RSPO3 SNV
(rs1892172, r2= 0.84 with rs9491696) (Fig. 1f, g and Supple-
mentary Fig. 1g, h). A cis-eQTL effect at rs9491696 was also
detected in abdominal AT from the TwinsUK study (Supple-
mentary Table 4). No eQTL signal was evident in the skin or
lymphoblastoid cell lines from the same TwinsUK subjects and
no other gene localised within 1 MB of rs9491696 was associated
with an eQTL in any tissue in this cohort or in GTEx. Formal co-
localisation analysis confirmed that the WHRadjBMI GWAS
association represented by rs9491696 and the abdominal AT cis-
eQTL were explained by the same causal SNVs (Fig. 1c). AEI
analyses in fractionated AT from 19 females (Supplementary
Table 7) further established that the WHRadjBMI-increasing
allele at rs9491696 was associated with increased RSPO3
expression specifically in mature adipocytes (Fig. 1h, i). Weaker
AEI signals were also detected in mature adipocytes and
abdominal APs from 22 male subjects (Supplementary Fig. 1i, j
and Supplementary Table 7). All individuals included in the AEI
analyses where homozygous for the common allele at rs72959041.
We conclude that the WHRadjBMI-associations attributable to
the RSPO3 locus are a consequence of increased AT RSPO3
expression possibly as a result of sequence variation in adipocyte
enhancers within intron 1 of RSPO3.
Increased AT RSPO3 expression impacts adipocyte size. We
investigated the link between increased adipose RSPO3 expression
and AT morphology by histological assessment of abdominal and
gluteal fat biopsies from 15 age- and BMI-matched pairs of
females heterozygous for the WHRadjBMI-raising allele or
homozygous for the ancestral allele at rs72959041 (Supplemen-
tary Table 8). This revealed that median adipocyte size was
increased in the gluteal depot of WHRadjBMI-increasing variant
carriers, due to a lower proportion of small adipocytes (Fig. 1j–m
and Supplementary Fig. 2). No difference in abdominal adipocyte
size was detected between the two genotypes despite the
WHRadjBMI-increasing allele at rs72959041 being associated
with increased android fat mass (Table 1).
RSPO3 is expressed in a sex- and depot-specific manner in AT.
To gain mechanistic insights into how RSPO3 modulates fat
distribution and adipocyte size we measured RSPO3 mRNA
abundance in paired abdominal and gluteal fat biopsies from 200
adults. RSPO3 expression was sexually dimorphic, being higher in
males and was greater in abdominal versus gluteal fat (Fig. 2a).
RSPO3 mRNA levels were also higher in visceral compared to SC
AT in both sexes (Fig. 2b). We additionally analysed RSPO3
expression in fractionated abdominal and gluteal AT from 61
females, 43 of whom had undergone a concomitant DXA scan to
assess their fat distribution (Supplementary Table 9). RSPO3
mRNA abundance was greater in mature adipocytes versus APs
and in abdominal versus gluteal adipocytes (Fig. 2c). Finally, we
asked if upper- compared with lower-body fat distribution wasT
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associated with differential AT RSPO3 expression. In age- and
percent fat mass-adjusted partial correlations, gluteal AP RSPO3
expression correlated negatively with gynoid and leg fat mass
(Table 2). No correlations between abdominal AP RSPO3 mRNA
levels or mature adipocyte RSPO3 expression and fat distribution
were detected in this cohort.
RSPO3 modulates AP and adipocyte biology. After mapping the
expression profile of RSPO3 in human AT we investigated its role
in AP biology using immortalised APs generated from paired
abdominal (imAbdo) and gluteal (imGlut) fat biopsies from a
healthy adult male26,27. Stable RSPO3 knockdown (KD) in these
cells (Fig. 3a) led to reduced imAbdo AP proliferation (Fig. 3b)
and enhanced adipogenesis in both imAbdo and imGlut cells
(Fig. 3c–f). Despite identical percentage KD (~ 45%) the pro-
adipogenic effect of RSPO3-KD was more pronounced in imGlut
versus imAbdo APs. RSPO3-KD in primary APs from a female
subject recapitulated these findings although, adipogenesis was
only augmented in gluteal cells (Fig. 3g–j). Finally, RSPO3-KD in
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Fig. 1 Allelic expression imbalance of RSPO3 and histological studies in abdominal and gluteal AT. a Schematic illustration showing alleles of the
sentinel SNP rs72959041 and the tagging SNP rs577721086. b Allelic expression analysis of RSPO3 transcripts was performed by qRT-PCR in abdominal
and gluteal AT cDNA from 14 heterozygous carriers at rs72959041 (seven females, seven males). The proportion of total cDNA and gDNA containing the
(WHR-increasing) rs577721086-C allele (r2= 0.98 with rs72959041-A) is quantified on the y-axis. Error bars are median values with 95% confidence
intervals. Statistical significance was assessed by two-tailed paired Student’s t-tests versus gDNA. c RSPO3 WHRadjBMI GWAS signals co-localise with
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significance was assessed by two-tailed paired Student’s t-tests versus gDNA. j–m Median adipocyte cell weight calculated from median cell area
measured from j abdominal and l gluteal AT histological sections from 14 and 15 pairs, respectively, of age- and BMI-matched females grouped by
rs72959041 genotype. Cumulative frequency distribution of the adipocyte cell-surface area are shown for abdominal (k) and gluteal (m) AT. More than
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minimum values. Statistical significance was assessed by a two-tailed Wilcoxon signed-rank test. Source data are provided as a Source Data file.
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primary visceral progenitors led to enhanced adipogenesis and
impaired proliferation (Supplementary Fig. 3). In reciprocal gain-
of-function experiments, treatment with recombinant human
RSPO3 stimulated proliferation in primary abdominal APs while
inhibiting adipogenesis, more robustly in primary gluteal cells
(Fig. 3k–m). The anti-adipogenic effect of RSPO3 was more
pronounced in the presence of foetal bovine serum (FBS), which
has been shown to promote WNT secretion from cultured
cells28,29. Consistent with the phenotypic effects of RSPO3-KD,
KD of LGR4, the predominant RSPO receptor expressed in AT
(data from GTEx), impaired proliferation selectively in primary
abdominal APs while stimulating adipogenesis more robustly in
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Fig. 2 RSPO3 expression in human abdominal and gluteal whole AT and AT fractions. Normalised RSPO3 mRNA levels in: a paired SC abdominal (Abdo)
versus gluteal (Glut) fat biopsies from healthy women (n= 103) and men (n= 97), b paired visceral versus SC abdominal AT from 11 women and 16 men,
and c fractionated AT [cultured APs and isolated mature adipocytes (ADS)] from 59 women. Histogram data are means ± s.e.m. **p < 0.01, ***p < 0.001,
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tailed paired Student’s t-tests for b and c. Source data are provided as a Source Data file.
Table 2 Partial correlations (Spearman’s) of measures of body-fat distribution (DXA), with RSPO3 mRNA levels from abdominal
and gluteal adipose tissue fractions from 43 women, adjusted for age, % total fat mass and menopause status.
Traits SC abdominal APs Gluteal APs Abdo ADS Glut ADS
rho p rho p rho p rho p
Android/gynoid fat ratio 0.143 0.4 0.331 0.04 −0.126 0.4 −0.071 0.7
Android/leg fat ratio 0.105 0.5 0.290 0.07 −0.121 0.5 −0.052 0.7
Android fat mass (g) −0.036 0.8 −0.186 0.3 0.123 0.4 0.172 0.3
SC android fat mass (g) −0.038 0.8 −0.339 0.03 0.075 0.6 0.044 0.8
Android visceral fat mass (g) 0.099 0.6 0.216 0.2 0.004 1 0.104 0.5
Gynoid fat mass (g) −0.137 0.4 −0.441 0.005 0.207 0.2 0.131 0.4
Leg fat mass (g) −0.121 0.5 −0.440 0.005 0.139 0.4 0.102 0.5
Tissue android, %fat 0.134 0.4 0.201 0.2 −0.115 0.5 0.033 0.8
Tissue gynoid, %fat −0.320 0.047 −0.355 0.03 0.162 0.3 −0.029 0.9
Tissue leg, %fat −0.174 0.3 −0.257 0.1 0.096 0.6 −0.117 0.5
APs adipose progenitors, ADS adipocytes, DXA dual-energy X-ray absorptiometry, SC, subcutaneous.
Significant p-values are given in bold. Source data are provided as a Source Data file.
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gluteal cells (Supplementary Fig. 4). We conclude that in vitro
RSPO3 appears to primarily inhibit gluteal AP differentiation
while stimulating proliferation of abdominal APs.
Given that WHRadjBMI-associated variants at RSPO3 act
primarily to modulate RSPO3 expression in mature adipocytes we
also examined the effects of induced RSPO3-KD on adipocyte
function, using de-differentiated fat (DFAT) cells generated from
imAbdo and imGlut adipocytes. These retain their distinct
cellular identities and many of their depot-specific gene
expression signatures30 (Supplementary Figs. 5 and 7a) and have
a higher adipogenic potential compared to primary and
immortalised APs (Fig. 4a). We focused initially on glucose
uptake and lipolysis since the insulin signalling and intracellular
lipolysis pathways have been genetically linked to the regulation
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of fat distribution11,31,32. Forty-eight-hour doxycycline treatment
led to efficient RSPO3-KD in both abdominal and gluteal in vitro
differentiated DFAT adipocytes without affecting lipid accumula-
tion or adipogenic gene expression (Fig. 4b, c and Supplementary
Fig. 6). Adipocyte RSPO3-KD was not associated with changes in
basal or insulin-stimulated glucose uptake (Fig. 4d, e), or in basal
or isoproterenol-induced lipolysis (Fig. 4f, g). We additionally
undertook transcriptional profiling of in vitro differentiated
RSPO3-KD DFAT cells using RNA sequencing (RNA-seq)
(Fig. 4h and Supplementary Fig. 7). Gene-set enrichment analysis
identified positive regulation of cell death as the top biological
process enriched in the cluster of genes differentially regulated in
RSPO3-KD adipocytes (Fig. 4i). Consistent with these findings,
doxycycline-induced RSPO3-KD rendered gluteal, but not
abdominal, DFAT adipocytes more resistant to TNFα-induced
apoptosis as determined by caspase-3/7 activity assays (Fig. 4j, k
and Supplementary Fig. 8). Collectively, these findings indicate
that in vitro RSPO3 modulates AP and adipocyte biology in a
depot-dependent manner.
RSPO3 regulates WNT signalling in APs. We next examined if
the biological activity of RSPO3 in APs was mediated by WNT
signalling. RSPO3-KD in imAbdo and primary abdominal APs
led to reduced WNT/β-catenin signalling as determined by
decreased expression of the universal β-catenin target gene
AXIN2 and reduced active β-catenin and phosphorylated LRP5/6
(pLRP5/6) protein levels, which are additional markers of cano-
nical WNT pathway activation (Fig. 5a–c). In contrast, RSPO3-
KD in imGlut and primary gluteal cells paradoxically led to
increased canonical WNT signalling (Fig. 5a–c). We confirmed
these results using RSPO3-KD imAbdo and imGlut cells stably
expressing the TOPflash promoter reporter, which monitors
endogenous β-catenin transcriptional activity (Fig. 5d). KD of
LGR4 recapitulated the effects of RSPO3-KD on WNT/β-catenin
signalling (Supplementary Fig. 9). Finally, we examined the
consequences of RSPO3-KD on non-canonical WNT signalling
(Fig. 5e, f). RSPO3-KD was associated with increased JNK
phosphorylation, a marker of planar cell polarity WNT pathway
activation, in abdominal APs and reduced CAMKII phosphor-
ylation, a marker of WNT-calcium signalling, in gluteal cells.
Thus, consistent with its depot-specific effects on AP function,
RSPO3 activates distinct WNT pathways in abdominal and glu-
teal APs in vitro.
A rspo3 mutation alters regional adiposity in zebrafish. To
verify that RSPO3 modulates AT biology in vivo we investigated a
zebrafish line (sa14295) harbouring a mutation, which induces a
premature stop codon in the final exon of rspo3 (Fig. 6a)33. We
chose to use this animal model as targeted disruption of Rspo3 is
embryonic lethal in mice34 and since Rspo3 expression is negli-
gible in mouse mature adipocytes versus APs (Supplementary
Fig. 10). Compared with their wild-type (wt) siblings, rspo3sa14295
homozygous mutant (rspo3m/m) animals had ~ 73% lower rspo3
expression in abdominal AT, encompassing the SC abdominal
and visceral depots, and ~ 92% lower rspo3 expression in per-
ipheral AT, comprising the SC AT on the lateral flank (Fig. 6b).
Nile Red staining of AT-localised lipid revealed that rspo3m/m
adults had significantly increased generalised adiposity versus wt
siblings which, after adjustment for total body area, was only
significant in females (Fig. 6c, d and Supplementary Fig. 11a–d).
The enhanced adiposity in rspo3m/m females was driven by
increases in the size of both abdominal and peripheral fat depots
(Supplementary Fig. 11e, f) although peripheral AT expansion
was more pronounced, leading to reduced abdominal-to-
peripheral fat ratio (Fig. 6e and Supplementary Fig. 11g).
rspo3m/m females also exhibited increased adipogenic (pparγ)
gene expression in the abdominal depot (Fig. 6f). Finally, reduced
rspo3 expression was associated with impaired proliferation, as
evidenced by diminished EdU incorporation in abdominal adi-
pose nuclei and adipocyte hypertrophy (Fig. 6g–i). Enhanced
adiposity and adipocyte hypertrophy were confirmed in rspo3m/m
juveniles prior to overt sexual differentiation (Supplementary
Fig. 11h–n). In summary, Rspo3 inhibits AT expansion in vivo in
zebrafish in a sex- and depot-specific manner.
Discussion
The work described herein extends GWAS findings by demon-
strating, through (1) co-localisation of the GWAS and adipose
cis-eQTL signals, (2) in vitro functional studies in abdominal and
gluteal APs and adipocytes and (3) in vivo adipose phenotyping
of rspo3 mutant zebrafish, that RSPO3 is the effector gene and
AT the target tissue of the WHRadjBMI associations at the
RSPO3 locus. The demonstration that both rs72959041 and
rs9491696 are additionally quantitative trait loci for plasma
RSPO3 protein levels further supports this conclusion35. We also
show that increased RSPO3 expression in SC fat is associated with
impaired peripheral AT storage capacity and concomitant
expansion of the android fat depots, in keeping with the insulin
resistance phenotypes observed in carriers of WHRadjBMI-
increasing alleles at this locus (Supplementary Table 1 and
refs. 36,37). Consistent with these data as well as our in vitro
studies, increased RSPO3 mRNA abundance in SC adipocytes
was also associated with increased gluteal adipocyte size in female
subjects. Enlarged adipocytes have been shown to be associated
with AT dysfunction, decreased adipogenic gene expression and
systemic insulin resistance in humans38–40. Based on our gene
Fig. 3 Effects of RSPO3-KD and recombinant human RSPO3 (rhRSPO3)-treatment on SC abdominal and gluteal AP biology. a–f Effects of RSPO3-KD in
immortalised (im) APs. a RSPO3-KD was confirmed by qRT-PCR (Abdo, n= 7 experiments; Glut, n= 9 experiments). b RSPO3-KD results in increased
doubling time in imAbdo but not imGlut APs. Doubling time of control (shCON) and RSPO3-KD (shRSPO3) imAbdo (n= 15 experiments) and imGlut APs
(n= 14 experiments). c–f RSPO3-KD promotes adipogenesis more robustly in imGlut versus imAbdo cells. Representative micrographs of shCON and
shRSPO3 imAbdo and imGlut cells after 14 days of differentiation are shown (c). Scale bar= 500 μm. Adipogenesis was assessed by d AdipoRed staining
(four independent experiments, n= 12 replicates each, expressed as relative lipid levels), and e–f qRT-PCR of adipogenic genes (n= 5 experiments).
g–j Effects of RSPO3-KD in primary (1°) APs. (g) RSPO3-KD was confirmed by qRT-PCR (n= 6 experiments). RSPO3-KD leads to increased doubling time
in 1°Abdo APs (n= 6 experiments) (h) and enhanced adipogenesis in 1° Glut cells (five independent experiments) (i). Representative micrographs of
AdipoRed-stained control and shRSPO3 cells at differentiation day 12 are shown (j). Intracellular lipids are stained yellow. Scale bar= 200 μm. k–m Effects
of rhRSPO3 treatment on 1° AP (k) proliferation (n= 15 [cells from three female subjects]), and l–m adipogenesis under l serum-free conditions (n= 13
independent experiments [cells from seven female donors]) and m in the presence of serum (FBS) (n= 2 independent experiments, eight replicates each).
veh., vehicle; R3 (5), 5 ng ml−1 rhRSPO3; R3 (50), 50 ngml−1 rhRSPO3. (a, b, d–i, m) Histogram data are means ± s.e.m. k, l Error bars are median values
with interquartile ranges. *p < 0.05, **p < 0.01, ***p < 0.001. Statistical significance was assessed by two-tailed Student’s t-test (a, b, e–i, paired; d, m,
unpaired, and with Bonferroni correction for m) and a two-tailed Wilcoxon signed-rank test (k, l). Source data are provided as a Source Data file.
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expression and AEI data we hypothesise that the sexually
dimorphic pattern of WHRadjBMI associations observed at the
RSPO3 locus, with stronger effects in females, stems from the
lower baseline RSPO3 expression in female SC AT. Our AEI
analyses and collective findings also support a model whereby
RSPO3 modulates regional adiposity via both autocrine and
paracrine actions. The latter involve facilitating crosstalk between
mature adipocytes and APs, in keeping with its mode of action in
other organs and tissues (e.g., liver, gut, adrenal gland) where it
functions as a local microenvironment-derived signal to modulate
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the growth, renewal and differentiation potential of stem and
progenitor cells41–44. Indeed, in rodents, the AP activation that
drives adipocyte hyperplasia in obesity was shown to be regulated
by the adipose depot microenvironment45.
Consistent with the distinct developmental origin of different
fat depots and a role for RSPO3 in modulating fat distribution,
AT RSPO3 mRNA abundance exhibited a central-to-peripheral
gradient; visceral > abdominal > gluteal AT. SC AT RSPO3
expression was also higher in males than females in keeping with
the increased male propensity to accumulate upper-body fat.
Based on fractionated AT data from females, gluteal AP RSPO3
expression correlated selectively and negatively with lower-body
fat accrual. In agreement with this finding, RSPO3-KD enhanced
adipogenesis preferentially in gluteal progenitors in vitro.
Fig. 4 Effects of doxycycline-induced RSPO3-KD on lipolysis, glucose uptake, and gene expression changes in in vitro differentiated DFAT cells. a Light
microscopy of abdominal and gluteal DFAT stable cell lines after 14 days adipogenic differentiation. Scale bar= 100 μm. b, c Expression of RSPO3 in DFAT
stable cell lines at day 15 of adipogenic differentiation following ~ 48-h treatment with 0.05 µg ml−1 doxycycline versus vehicle in hormone-free basal media
(n= 5 experiments). d, e Insulin-stimulated glucose uptake in DFAT cells relative to basal glucose uptake following ~ 48-h treatment with 0.05 µg ml−1
doxycycline or vehicle in hormone-free basal media (n= 12, from four independent experiments). f, g Isoproterenol-stimulated glycerol release in
DFAT cells relative to basal glycerol release following ~ 48-h treatment with 0.05 μg ml−1 doxycycline or vehicle (n= 12, from four independent
experiments). b–g Histogram data are means ± s.e.m. *p < 0.05, **p < 0.01. Statistical significance was assessed by two-tailed paired (b, c) and unpaired
(d–g) Student’s t-test comparing doxycycline versus vehicle treatment. h, i Transcriptional profiling of in vitro differentiated abdominal and gluteal
DFAT cells following 48-h doxycycline-induced RSPO3-KD. h Number of differentially expressed (DE) genes. FDR p < 0.05. i Gene-set enrichment analysis
results of DE genes in gluteal DFAT dox-induced RSPO3-KD cells showing the top 10 GO biological processes. j, k Effect of doxycycline-induced RSPO3-KD
in differentiated j abdominal, and k gluteal cells on apoptosis in the presence of indicated concentrations of rhTNFα (ngml−1). Apoptosis was assayed
using Caspase Glo 3/7 reagent. Results are shown as a % of luminescence of non-dox (vehicle)-treated cells in the presence of the same concentration of
rhTNFα (n= 7 independent experiments). Statistical significance was assessed by a two-tailed Wilcoxon signed-rank test comparing dox and non-dox
treated cells. Solid symbols, tet-shCON cells; open symbols, tet-shRSPO3 cells; circles, no rhTNFα; squares, 10 ngml−1 rhTNFα; triangles, 100 ngml−1
rhTNFα. Error bars are median values with interquartile ranges. Source data are provided as a Source Data file.
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Directionally opposite results were observed in gain-of-function
studies. The weaker effects of recombinant RSPO3 on AP biology
in these latter experiments may be because RSPOs (and WNTs)
are generally tightly associated with cell membrane and extra-
cellular matrix proteoglycans, which are essential for efficient
signalling46. Based on transcriptome-wide profiling and caspase-
3/7 activity assays we speculate that RSPO3 may further restrain
expansion of the gluteofemoral depot by increasing the suscept-
ibility of gluteal adipocytes to apoptotic stimuli. We also hypo-
thesise on the basis of our in vitro findings that RSPO3 may
additionally promote centripetal fat deposition by stimulating
expansion of the AP pool in the abdominal (and visceral) depots.
In this regard, RSPO3 was shown to function as an organ size
rheostat in the liver and gut by stimulating hepatocyte and
intestinal progenitor cell proliferation respectively18,47. Animal
studies have also demonstrated that AP number plays a critical
role in determining the size of adult fat depots. Specifically,
activation of PI3K-AKT signalling selectively in Myf5+ mouse
mesenchymal precursors was shown to lead to an increase in AP
numbers and profound lipomatosis. Strikingly, because mouse
ATs are composed of varying proportions of Myf5+ and Myf5−
progenitors, these animals displayed marked changes in fat dis-
tribution48. Recapitulating these findings, activating mutations in
the PI3K-AKT pathway in humans lead to segmental AT over-
growth syndromes49–51. Finally, in vivo studies in mice have
shown that PI3K-AKT2-induced AP proliferation is indis-
pensable for hyperplastic AT growth during adulthood and
contributes directly to the differential fat distribution between the
sexes45,52,53. Notably, rare loss-of-function AKT2 mutations in
humans are associated with partial lipodystrophy and severe
insulin resistance54.
The distinct biological responses elicited by RSPO3 in
abdominal versus gluteal APs in vitro were driven by the capacity
of RSPO3 to differentially modulate WNT signalling in these two
cell types. While RSPO3-KD led to inhibition of WNT/β-catenin
signalling in abdominal progenitors, the opposite was true in
gluteal cells. Given that β-catenin is an oncogene, these findings
are consistent with the diminished proliferative capacity selec-
tively seen in RSPO3-KD abdominal APs. Interestingly, a recent
study found that RSPO3 knockout led to increased proliferation
in SGBS cells55; an AP line derived from a human infant with
Simpson–Golabi–Behmel syndrome56. This provides further
evidence that RSPO3 may have cell-type specific effects on AP
proliferation and presumably WNT/β-catenin signalling. In
contrast, the enhanced differentiation potential of RSPO3-KD
gluteal cells may be driven by non-canonical WNT signalling
since the WNT/β-catenin pathway is generally thought to inhibit
adipogenesis. Consistent with this possibility RSPO3-KD was
associated with inhibition of WNT-calcium signalling selectively
in gluteal cells.
In keeping with the results of the human studies, a nonsense
mutation in rspo3 in zebrafish was associated with increased
generalised adiposity. Strikingly, changes in adiposity were more
pronounced in female versus male adult fish consistent with the
sexual dimorphism of the WHRadjBMI GWAS associations
observed at the human RSPO3 locus12. Furthermore, this phe-
notype was independent of total body area, a reliable metric for
body weight in wild-type zebrafish (see methods) and as such was
likely to be driven by changes in AT biology rather than central
nervous system effects on energy balance. We acknowledge that
the close relationship between body area and body weight may be
distorted in rspo3 mutants consequent to changes in body com-
position. Nonetheless, given that in absolute terms the increased
adiposity in female mutants was ~3-fold higher than wild-type
animals it is unlikely that any under- or over-estimation of body
weight based on surface area would have altered this result.
rspo3m/m females also exhibited altered fat distribution in keeping
with depot- and/or dose-dependent effects of Rspo3 on AT
expansion and consistent with an earlier report demonstrating
that rspo3 regulates anteroposterior patterning in zebrafish
embryos57. Finally, this mutation was associated with impaired
proliferation concomitant with adipocyte hypertrophy in
abdominal AT. These data provide additional evidence that
genetic mechanisms controlling regional adiposity are conserved
between mammals and fish58.
Our study has limitations. Specifically, APs undergo significant
changes in gene expression when grown on tissue culture plastic
and comprise a heterogeneous collection of cells thereby making
it difficult to draw cell autonomous conclusions. For example, the
pro-proliferative effect of RSPO3 in abdominal cells could have
inhibited adipogenesis via non-cell autonomous effects (e.g., a
non adipogenic cell out proliferating the adipogenic cells). Hence,
it is uncertain whether the distinct biological responses elicited by
RSPO3 in abdominal and gluteal cells in vitro are preserved
in vivo and further studies, e.g., employing stable isotopes to
determine in vivo cell turnover in the abdominal and gluteal AT
of different RSPO3 genotype carriers are necessary to establish
this. Additionally, we did not take into consideration the potential
of eggs accounting for the increased body area in the female rspo3
mutant zebrafish. If this were true however, we have under-
rather than over-estimated the increased body-fat percentage
relative to body area of these animals. We also opted to express
the body-fat data as a percentage of surface area rather than
weight, to control for differences in zebrafish size.
In summary, we demonstrate that AT-specific regulation of
RSPO3 mediates the WHRadjBMI genetic associations at the
corresponding locus. Consistent with this finding, RSPO3 appears
to have depot-specific effects on AP and adipocyte biology
in vitro, which in APs are mediated at least partly, via modulation
of WNT signalling. Our data reinforces the notion that devel-
opmental genes play an important role in hardwiring AP and
adipocyte identity and support a role for RSPO3 as a secreted
signal mediating crosstalk between adipocytes and APs to mod-
ulate AT expansion.
Methods
Study population, body-fat measurements and AT sampling. The OBB (www.
oxfordbiobank.org.uk) is a population-based cohort of 30–50-year-old healthy
subjects, recruited from Oxfordshire in the UK, from whom basic anthropometric
data were recorded and fasting blood samples taken for DNA and plasma chem-
istry. Menopause status of female subjects was determined by questionnaire. Peri-
menopausal females <51 years were assigned as pre-menopausal, and those ≥51
years as post-menopausal, based on 51 years being the average menopause age in
the UK. Whole-body DXA was performed using a Lunar iDXA scanner (GE
Healthcare, Little Chalfont, U.K.) and the acquired images processed using the
enCORE v14.1 software. Paired SC abdominal and gluteal AT biopsies were
obtained from adult subjects by needle biopsy from the periumbilical and buttock
areas. Paired SC abdominal and visceral fat samples were obtained from patients
undergoing elective surgery as part of the MolSURG study. All studies were
approved by the Oxfordshire Clinical Research Ethics Committee (NRES Com-
mittee South Central-Oxford C, 08/H0606/107+5, IRAS project ID 136602), and
all volunteers gave written, informed consent.
Genotyping of OBB subjects. OBB subjects were genotyped on the Illumina
Human Exome BeadChip and Affymetrix UK Biobank Axiom arrays. Genotype
imputation was performed using the Affymetrix UK Biobank Axiom array with
Haplotype Reference Consortium (HRC), 1000Genome and UK10K reference
panels using IMPUTE2 software.
Adipose tissue histology and cell sizing. AT biopsies were fixed in 10% neutral
buffered formalin, embedded in paraffin wax, cut into 5 µm sections, and stained
with haematoxylin and eosin. Sections were viewed and photographed at x200
magnification, and adipocyte cross-sectional area was measured using Adobe
Photoshop 5.0.1 (Adobe Systems, San Jose, CA) and Image Processing Tool Kit
(Reindeer Games, Gainesville, FL). Adipocyte volume and weight were calculated
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for each individual using the following formulae:
V ¼ π ´ d
3
6
ð1Þ
w ¼ V ´ 0:915 ð2Þ
V= cell volume (µm3), d (real cell diameter)= histological cell diameter (µm) x
1.1, w=weight of a single adipocyte (x10−12 g), density of fat cell triglycerides=
0.915 g ml−1. Adipocytes were assumed to be spheres.
Cell lines. Primary APs were separated from mature adipocytes by centrifugation
following ~ 1-h collagenase (Roche)-digestion (1 mgml−1 in Hanks’ buffered salt
solution) of AT biopsies. Immortalised APs were generated by transgenesis of
primary APs with human telomerase reverse transcriptase and HPV-E7 onco-
protein. De-differentiated fat (DFAT) cells were derived from immortalised human
AP cells as follows: AP cells were differentiated in the presence of 50 ng ml−1
recombinant human BMP2, and 180 µM fatty acid mix (oleate 75 µM, palmitate
65 µM, linoleate 40 µM complexed to 10% BSA) was added from differentiation
day 7 onwards. Culture media containing detached, well-differentiated, lipid laden
cells were transferred to inverted 9 cm2 slide flasks filled with standard growth
media for ceiling culture, and allowed adhere and de-differentiate for 3–5 days. The
flasks were then inverted and the media was replaced with fresh standard growth
media to allow de-differentiated cells to proliferate. The resulting DFAT AP
daughter cells have high adipogenic capacity.
Cell culture and differentiation of human APs. APs were grown in Dulbecco’s
modified Eagle’s medium nutrient mixture F-12 Ham (DMEM-F12) supplemented
with 10% fetal bovine serum (FBS), 2 mM L-glutamine, 0.25 ng ml−1 fibroblast
growth factor, 100 units ml−1 penicillin and 100 µgml−1 streptomycin. For dif-
ferentiation of APs to adipocytes, confluent cells were cultured for 14–18 days in a
standard adipogenic medium (DMEM-F12 containing 2 mM L-glutamine, 100
units ml−1 penicillin, 100 µg ml−1 streptomycin, 17 µM pantothenate, 100 nM
human insulin, 10 nM 3,3’,5-triiodo-L-thyronine, 33 µM biotin, 10 µg ml−1 human
transferrin and 1 µM dexamethasone). For the first 4 days, 250 µM 3-isobutyl-1-
methylxanthine and 4 μM troglitazone were added to the adipogenic medium. For
quantitative measurement of intracellular lipid, APs were differentiated in type I
collagen-coated 96-well plates, then assayed using the AdipoRed assay reagent
(Lonza) and a CytoFluor Multi-well Plate Reader series 4000 (PerSeptive Biosys-
tems) or an EnSpire 2300 Multilabel Reader (Perkin Elmer). To study the effect of
recombinant human (rh) RSPO3 (3500-RS, R&D Systems) treatment on adipo-
genesis, confluent cells were cultured for 2 days in the presence of rhRSPO3 or
vehicle, then differentiated throughout in the presence of rhRSPO3 or vehicle in
standard adipogenic medium, or serum-containing adipogenic medium (DMEM-
F12 containing 10% FBS, 2 mM glutamine, 100 units ml−1 penicillin, 100 µg ml−1
streptomycin, 100 nM human insulin and 1 µM dexamethasone), and assayed
as above.
Lentiviral constructs and generation of stable cell lines. RSPO3 (shRSPO3,
TRCN0000056663) and control shRNA plasmid vectors were purchased from
Sigma-Aldrich. The LGR4 (shLGR4, TRCN0000004742) shRNA plasmid vector
was purchased from Thermo Fisher Scientific. The 7xTcf-FFluc//SV40-mCherry
(7TFC) TOPflash reporter lentiviral vector59 was a gift from Roel Nusse (Addgene
#24307). Lentiviral particles were produced in HEK293 cells (ATCC, CRL-1573)
using MISSION® (Sigma-Aldrich) packaging mix. Stable cell-lines were generated
by lentiviral transduction and selection in 2 μg ml−1 puromycin26.
Proliferation assays. T75 or T175 flasks were seeded with equal numbers of
control or KD cells. Cells were trypsinised and double counted using a haemo-
cytometer or a Cellometer Auto T4 (Nexcelom Bioscience), every 96 h. Doubling
time was calculated using the formula:
Td ¼ t2  t1ð Þ ´ log 2ð Þ  log q2  q1ð Þ½  ð3Þ
where t= time (days), q= cell number. To study the effects of rhRSPO3 treatment,
cells seeded in 96-well plates were cultured in the presence of 5 ng ml−1 rhRSPO3
or vehicle for up to 5 days. One plate of cells was assayed each day using
CyQUANT Direct Cell Proliferation Assay and doubling time was calculated
as above.
Luciferase reporter assay. To study the effects of RSPO3-KD on TOPflash
activity, control and shRSPO3 cells expressing the 7TFC reporter vector59 were
grown to confluence in 96-well plates in complete growth media, then treated with
indicated concentrations of rhWNT3A (5036-WN, R&D Systems) or vehicle in
serum-free media for 20 h. To assess LGR4-KD on TOPflash activity, control and
shLGR4 cells expressing 7TFC were treated with rhRSPO3 or vehicle in serum-free
media for 24 h. TOPflash reporter activity was measured using the Luciferase Assay
System (Promega) on a Veritas Microplate Luminometer (Turner Biosystems).
Luciferase results were corrected to mCherry fluorescence intensity to adjust for
differences in copy number of 7TFC in the different cell-lines.
Doxycycline-inducible RSPO3-KD in adipocytes. To study the effects of RSPO3-
KD in in vitro differentiated adipocytes, oligonucleotides for shRSPO3 (top: 5ʹCC
GGGCTGTGCAACATGCTCAGATTCTCGAGAATCTGAGCATGTTGCACAG
CTTTTT; bottom: 5ʹAATTAAAAAGCTGTGCAACATGCTCAGATTCTCGAG
AATCTGAGCATGTTGCACAGC), and shCON
(top: 5ʹCCGGCAACAAGATGAAGAGCACCAACTCGAGTTGGTGCTCTT
CATCTTGTTGTTTTT;
bottom: 5ʹAATTAAAAACAACAAGATGAAGAGCACCAACTCGAGTTGGT
GCTCTTCATCTTGTTG) were annealed and cloned into the tet-pLKO-puro
doxycycline-inducible expression lentiviral vector [kind gift of Dmitri Wiederschain
(Addgene #21915)]60. DFAT preadipocyte cells stably transduced with the tet-
pLKO-puro-shRSPO3 (tet-shRSPO3) or tet-pLKO-puro-shCON (tet-shCON)
lentiviral vectors were maintained in tetracycline-free media [DMEM-
F12 supplemented with 10% FBS (ThermoFisher Scientific Gibco, #26140079),
2 mM L-glutamine, 0.25 ngml−1 fibroblast growth factor, 100 units ml−1 penicillin
and 100 µgml−1 streptomycin, and 2 μg ml−1 puromycin], and differentiated in
standard adipogenic media. Differentiated cells were incubated in hormone-free
basal media (DMEM-F12 supplemented with 2mM L-glutamine, 100 units ml−1
penicillin, 100 µg ml−1 streptomycin, 17 µM pantothenate, 33 µM biotin, 10 µgml−1
human transferrin) containing either vehicle or 0.05 µgml−1 doxycycline (to induce
shRNA-expression) for 48 h prior to glucose uptake or lipolysis assays, or harvesting
for RNA and protein.
Glucose uptake assay. Forty-eight hours before glucose uptake assay, 12-well
plates of in vitro differentiated cells were starved in basal medium containing either
vehicle or 0.05 µg ml−1 doxycycline to induce RSPO3-KD. On treatment day, cells
were incubated in either fresh basal medium (to measure basal uptake) or basal
medium containing 25 nM insulin for 30 minutes at 37 °C, 5%CO2. Cells were then
washed twice in HEPES-buffered saline (HBS; 140 mM NaCl, 20 mM HEPES,
5 mM KCl, 2.5 mM MgSO4, 1 mM CaCl, pH7.4), incubated with 1 ml of uptake
buffer [10 µM 2-deoxy-D-glucose (2-DG) and 0.024 MBq (0.66 µCi) per ml 2-[3H]-
DG in HBS] for 10 min at room temperature, washed twice in ice-cold 0.9% NaCl,
and lysed in 1.2 ml 50 mM NaOH. Radioactivity was measured in liquid scintillant
(Perkin Elmer) in a Beckman LS6500 Multipurpose Scintillation Counter (Beck-
man). To determine nonspecific diffusion, cells without insulin treatment were
incubated with uptake buffer containing 10 μM Cytochalasin B to block facilitative
transport. Results were corrected for nonspecific diffusion, and normalised to
protein concentration. All experiments were performed in triplicate and repeated at
least three times.
Lipolysis. Basal and stimulated lipolysis was performed on in vitro differentiated
cells in 12-well plates as follows: 2 days before lipolysis experiment, differentiated
cells were incubated in basal media containing either 0.05 µg ml−1 doxycycline or
vehicle. On treatment day, cells underwent a 2-h wash out period in Krebs Ringer
HEPES (KRH) buffer containing 5 mM glucose and 3.5% bovine serum albumin
(BSA), then incubated for 2 h in fresh KRH buffer (for basal lipolysis) or KRH
buffer containing 10 nM isoproterenol (for stimulated lipolysis). At the end of the
2-h period, the treatment buffer was collected for glycerol measurements, and cells
harvested in lysis buffer containing 1% IGEPAL CA-630, 150 mM NaCl and
50 mM Tris-HCl pH 8.0 for protein. Glycerol concentrations were measured using
the GY105 enzymatic assay (Randox Laboratories Ltd) on an ILAB 650 clinical
analyser (Instrumentation Laboratory UK) and normalised to cellular protein
concentration.
Caspase-Glo 3/7 assay for apoptosis. Stably transduced DFAT cells were dif-
ferentiated in 96-well plates. On day 13 of differentiation, cells were treated with
0.05 μg ml−1 doxycycline (or vehicle) in hormone-free basal media for 24 h, then a
further 24 h with basal media containing 0, 10 or 100 ng ml−1 rhTNFα (Ther-
moFisher Scientific Gibco, #PHC3015), in the presence of 0.05 μg ml−1 doxycycline
or vehicle. Apoptosis was assayed using the Caspase-Glo 3/7 assay (Promega) and a
Veritas Microplate Luminometer (Turner Biosystems).
Zebrafish studies. All zebrafish experiments conformed to the U.S. Public Health
Service Policy on Humane Care and Use of Laboratory Animals, using protocols
approved by the Institutional Animal Care and Use Committee of Duke University.
Zebrafish were raised, fed, and housed as described58. The rspo3sa14295 allele was
generated by ENU mutagenesis. Twenty amino acids were truncated by the
induction of the nonsense mutation. Animals were obtained from the Wellcome
Trust Sanger Institute Zebrafish Mutation Project as F3 embryos after out-crossing
to Hubrecht long fin wt zebrafish in the previous generation. F3 adults were
subsequently out-crossed to the Ekkwill wt strain and F4 carriers inter-crossed for
experiments. Quantitative real-time PCR (qRT-PCR) primers were forward, 5ʹ-
AGATGCTGCTCCTCATTGCT, and reverse, 5ʹ-CTGGCCCCTGTTACACAGTT.
The reverse primer was used for sequencing. Zebrafish experiments were con-
ducted on adult (5-month-old) or postembryonic zebrafish (21 or 26 days post
fertilisation) wt sibling or rspo3m/m fish as below. Zebrafish staging was conducted
according to61,62. To control for body size and weight we utilised body area, which
is an accurate proxy for zebrafish body mass (mass (mg)= 4327.4627+
0.0004094*body area; R2= 0.95, n= 41; data used from ref. 63). We utilised
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multiple linear regression to control for the potential confounding effect of body
area on AT area measurements. Unless noted, no effect of body area on AT
measures was found.
Nile red staining of zebrafish adipose tissue. Five-month-old adult and post-
embryonic wt sibling or rspo3m/m fish were stained with Nile red and images were
obtained on a Leica M205 fluorescence stereoscope using a GFP bandpass filter.
Standard length, body area and whole-animal Nile Red signal intensity were
quantified in ImageJ/FIJI (v1.50a). To assess regional adiposity, background signal
was first subtracted from each image and Nile Red signal was segmented based on
pixel intensity. Generalised adiposity was expressed as a % of body area; peripheral
adiposity was assessed within a 400 μm2 ROI at the lateral SC depot (LSAT); and
abdominal AT was quantified using a 400 × 200 μm2 ROI centred at the abdominal
SC (ASAT) and pancreatic visceral (PVAT) depots.
Confocal imaging of zebrafish adipose tissue. Adult and postembryonic wt or
rspo3m/m animals were housed in 200 ml water system supplemented with 25 µM
EdU for 72 h. Representative abdominal (PVAT) and peripheral (LSAT) adipose
tissues were then dissected and fixed overnight in 4% paraformaldehyde. The
Click-iT imaging kit was used to detect EdU+ nuclei (Life Technologies, #C10338),
LipidTOX to detect lipid droplets (Life Technologies, #H34475), and Hoechst
33342 to detect nuclei (Life Technologies, #H3570). Samples were mounted, and z-
stacks collected on a Zeiss LSM780 confocal microscope. Images were processed,
segmented, and quantified.
RNA isolation and quantitative real-time PCR. Total RNA was extracted from
adipose tissue biopsies using TRIzol® reagent (Invitrogen) and cultured APs and
isolated adipocytes using the RNeasy Mini Kit (Qiagen). cDNA was synthesised
using the High Capacity cDNA Reverse Transcription kit (Applied Biosystems).
qRT-PCR assays were performed using TaqMan gene expression assays. Expres-
sion values were calculated by the ΔCT transformation method (ΔCT= efficiency
[calibrator Ct− sample Ct]) and normalised to PPIA and PGK1 in the case of tissue
samples, and 18S in the case of cultured cells and isolated adipocytes. Zebrafish AT
samples were dissected and RNA extracted using the QIAzol lysis reagent (Qiagen,
#79306) and the RNeasy lipid tissue mini kit (Qiagen, #74804). cDNA was syn-
thesised using the SuperScript III kit (Invitrogen, #18080). qRT-PCR data were
normalised to 18S. TaqMan assays and primers used are listed in Supplementary
Table 10.
Allele expression imbalance (AEI) studies. AEI studies were performed as fol-
lows: Briefly, qRT-PCR was performed on paired cDNA and genomic DNA
(gDNA) samples from individuals heterozygous for both rs9491696 or rs72959041
and their corresponding transcribed (tagging) SNV using a TaqMan allelic dis-
crimination assay to the tagging SNV (Life Technologies). To generate a standard
curve, qRT-PCR of three pairs of gDNA homozygous for each of the two alleles
mixed at different ratios (30:70, 40:60, 50:50, 60:40 and 70:30) were performed
concurrently. The standard curve was generated from the mean observed % of
effect allele (EA), which tags the WHRadjBMI risk allele. The observed % EA from
each experimental gDNA and cDNA sample was estimated from the standard
curve. Under idealised conditions, the observed % EA from heterozygous gDNA
would be 50%. Significant deviation in observed % of EA in cDNAs from that of
gDNA indicates the presence of AEI in RSPO3 expression.
Genetic credible sets. For each distinct GWAS association signal, we calculated
an approximate Bayes factor in favour of association on the basis of allelic effect
sizes and standard errors from the approximate conditional analysis adjusting for
all other index variants in the region. For the jth variant,
Λj ¼
ffiffiffiffiffiffiffiffiffiffiffiffiffi
Vj
Vj þ ω
s
exp
ωβ2j
2Vj Vj þ ω
 
2
4
3
5 ð4Þ
where βj denotes the estimated allelic effect (log-OR), Vj the corresponding var-
iance, and ω (=0.04)64 the prior variance in allelic effects. We then calculated the
posterior probability that the jth variant drives the association signal,
πj ¼
Λj
P
k
Λk
ð5Þ
We then constructed the 99% credible set of variants for each signal, by
ordering all variants in descending order of their posterior probability of
association and including variants until the cumulative posterior probability of
association reached 0.99. We then calculated the number of variants and length of
the genomic region covered by each 99% credible set.
Co-localisation of WHRadjBMI signals and SC AT cis-eQTL. To test the explicit
hypothesis that the GWAS association signals for WHRadjBMI and the sub-
cutaneous abdominal adipose tissue eQTLs at the RSPO3 locus are explained by the
same causal SNVs at the respective independent signals, we applied a Bayesian test
implemented in the R package coloc65. We used default priors supplied by the
coloc package (P1= 1 × 10−4, P2= 1 × 10−4, and P12= 1 × 10−5; prior prob-
abilities for association in the GWAS dataset, the eQTL dataset, and both) and a
threshold of PP3+ PP4 ≥ 0.99 and PP4/PP3 ≥ 5, a cutoff previously suggested66,
was used for “strong” evidence of co-localisation. Analysis was performed using
published meta-analysed WHRadjBMI GWAS summary statistics12 and sub-
cutaneous abdominal adipose tissue eQTL results from the TwinsUK study (see
below). For each association pair assessed for co-localisation, SNVs within 500 kb
of the lead SNV were considered. We obtained the effect estimates for each
independent association signal (for both GWAS and eQTL) by performing
approximate conditional analysis using GCTA67, adjusting for all other indepen-
dent variants in the RSPO3 region. We used a reference sample of ~6,000 unrelated
(pairwise relatedness < 0.025) individuals of white British origin, randomly selected
from the UK Biobank, to model patterns of LD between variants.
TwinsUK RSPO3 cis-eQTL analysis. The TwinsUK samples were genotyped on a
combination of Illumina chips, namely the HumanHap300, HumanHap610Q, 1M-
Duo and 1.2MDuo Illumina arrays. Samples were imputed using the Haplotype
Reference Consortium (HRC) reference panel (http://www.haplotype-reference-
consortium.org), using Minimac 3 on the Michigan Imputation Server (https://
imputationserver.sph.umich.edu). Genotype data were filtered to exclude SNVs
with HWE P < 1 × 10−6, imputation R2 < 0.8, or a minor allele frequency (MAF) <
0.01. RNA-seq expression data from subcutaneous adipose tissue were available for
766 twins. RNA-seq data were generated, quantified and normalised68. Expression
data were adjusted for family structure (family and zygosity) and 50 PEER factors
using mixed effects models fitted using the lmer function from the lme4 package in
R, and expression residuals used for ciseQTL analysis. Exon-level ciseQTL analysis
at the RSPO3 gene was conducted within a 2Mb window surrounding the tran-
scription start site using the MatrixeQTL package in R version 3.5.0, which
employs a standard additive linear model, with BMI, age and RNA extraction batch
included as covariates.
RNA-seq library preparation and analysis. DFAT tet-shCON and tet-shRSPO3
cells were differentiated by standard differentiation protocol. On day 13 of differ-
entiation, cells were treated with doxycycline (final concentration of 0.05 μg ml−1),
or vehicle, in hormone-free basal media, for 2 days. On day 15, cells were harvested
for RNA. RNA-seq was performed on samples from three independent experiments.
Total RNA purification and on-column DNase I-treatment were performed using
the RNeasy Mini kit (Qiagen). RNA concentration was assessed using the Nano-
Drop ND-1000 (Labtech) and RiboGreen (Invitrogen) on the FLUOstar OPTIMA
plate reader (BMG Labtech), and RNA quality using the Agilent 2100 Bioanalyzer
(Agilent) and the 2200 or 4200 TapeStation (Agilent, RNA ScreenTape). RNA
integrity number (RIN) estimates for all samples were between 7 and 10. Library
preparation, cDNA sequencing and bioinformatics analysis were performed at the
Oxford Genomics Centre (Wellcome Trust Centre for Human Genetics, Oxford,
UK). Differential gene expression analysis was performed with the edgeR package69,
with multiple testing correction using edgeR’s default Benjamini-Hochberg method
for controlling the false-discovery rate (FDR). Gene-set enrichment analysis of
differentially expressed genes (FDR < 0.05) was performed in Metascape70. Full
protocol detailed in Supplementary Methods.
Western blotting. Whole-cell lysates were prepared in ice-cold lysis buffer con-
taining 50 mM Tris pH 8.0, 250 mM NaCl, 5 mM EDTA, 0.5% IGEPAL CA-630,
10 mM sodium fluoride, 1 mM sodium orthovanadate and protease inhibitors
(Complete EDTA-free, Roche), and quantified using the Bio-Rad DC Protein assay
kit. Equal amounts of protein were resolved by SDS-PAGE, transferred onto
polyvinylidene fluoride membrane (Bio-Rad), and incubated with indicated pri-
mary antibodies according to the manufacturer’s instructions, followed by the
appropriate horseradish peroxidase-conjugated secondary antibodies (DAKO), and
detection by enhanced chemiluminescence (GE Healthcare). Protein densitometry
was performed using Image J. Antibodies were from: Cell Signalling Technology
[phospho-LRP5/6-S1490 rabbit pAb (#2568, 1:1000), phospho-JNK (Thr183/
Tyr185) rabbit pAb (#9251, 1:1000)]; Merck Millipore [active β-catenin (8E7)
mouse mAb (05-665, 1:2000)]; Santa Cruz Biotechnology [total JNK mouse mAb
(sc-7345, 1:500), phospho-CaMKIIα (Thr286) rabbit pAb (sc12886-R, 1:250), total
CaMKII rabbit pAb (sc-9035, 1:500)]; Abcam [α-tubulin rabbit pAb (ab15246,
1:2000)]; and DAKO [horseradish peroxidase-conjugated secondary antibodies:
mouse IgG goat pAb (P0447, 1:1000); rabbit IgG goat pAb (P0448, 1:2000)].
Statistical analysis. Statistical analyses for association studies between RSPO3
SNVs and OBB quantitative traits were performed using PLINK v.1.07 (pngu.mgh.
harvard.edu/~purcell/plink/). All quantitative traits were log transformed and
analysed with an additive linear regression model adjusting a priori for age, sex and
% total fat mass. All other statistical analyses were performed using SPSS 22,
SigmaPlot 14.0 or GraphPad 7.04. Evidence for between-group differences were
assessed using a two-tailed paired or unpaired Student’s t-test, as appropriate,
unless otherwise specified.
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Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Full TwinsUK RNA-seq expression data from subcutaneous adipose tissue are available
by direct application to TwinsUK. Full GWAS summary statistics from the UK Biobank
meta-analysis for WHRadjBMI can be found on https://doi.org/10.5281/zenodo.1251813.
The source data underlying Figs. 1b, d, e, g–m, 2, 3a, b, d–i, k–m, 4b–k, 5, 6b, d–g, i,
Supplementary Figs. 1, 2, 3a–c, 4a, b, d–f, 5, 6, 7b–d, 8, 9, 10, 11a–c, e–g, i–l, n, and
Table 2 are provided as a Source Data file. RNA-seq data that support the findings of this
study have been deposited in GEO with the accession code GSE149294. All other relevant
data are available from the corresponding authors upon reasonable request.
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